<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614913</url>
  </required_header>
  <id_info>
    <org_study_id>OSR #48095</org_study_id>
    <nct_id>NCT00614913</nct_id>
  </id_info>
  <brief_title>Proton Beam Therapy for Treatment of Hepatocellular Carcinoma</brief_title>
  <official_title>Phase I/II Study of Proton Beam Therapy for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the possible benefits and side effects of the use of
      proton therapy for patients with hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is a type of primary cancer of the liver that is being
      diagnosed in the U.S. population with increasing frequency. While surgery is the first line
      of treatment, many patients are not eligible for surgical removal. Current non-surgical
      treatments for HCC are not fully effective and can have substantial side-effects. This study
      utilizes a type of radiation treatment called proton beam that can deliver high doses of
      radiotherapy to tumors within the liver while minimizing damage to surrounding healthy
      tissues. The treatment is non-invasive and is given on an out-patient basis over a three week
      coarse. The study will evaluate the effectiveness and side-effects of this therapy by
      tracking patient's outcomes following treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1998</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year Survival Without Tumor Progression for Patients Within the Milan Criteria</measure>
    <time_frame>3 months</time_frame>
    <description>Percent of participants alive and without tumor progression 3 years following treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Survival Without Tumor Progression</measure>
    <time_frame>3 months</time_frame>
    <description>Median time until disease progression or death</description>
  </primary_outcome>
  <enrollment type="Actual">76</enrollment>
  <condition>Liver Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton radiation therapy</intervention_name>
    <description>A total dose of 63 Gy will be delivered in 15 equally divided daily fractions over a 3 week coarse as an out-patient.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hepatocellular carcinoma

          -  Adult patients aged 18 years old and above

          -  Ability to give informed consent for study

          -  Compensated liver disease

        Exclusion Criteria:

          -  Pediatric patients (aged less than 18 years old)

          -  Decompensated or advanced liver disease

          -  Poorly controlled ascites

          -  Variceal hemorrhage within the previous 30 days

          -  Recurrent hepatic encephalopathy

          -  Cirrhosis with CTP* score &gt;10

          -  Active alcohol or drug abuse

          -  Anticipated survival of less than 30 days

          -  Advanced co-morbid medical illnesses

          -  Karnofsky Performance Score &lt;60

        Tumor characteristics:

        - Any tumor that can not be safely and effectively irradiated due to inability to deliver
        target treatment dose to required treatment volume or due to prohibitively high risk of
        anticipated toxicities to normal liver or nearby bowel, stomach, kidney or spinal cord.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Bush, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Dept. of Radiation Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerry D Slater, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Loma Linda University Department of Radiation Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center / James M. Slater Proton Treatment Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology. 2004 Nov;127(5 Suppl 1):S189-93.</citation>
    <PMID>15508084</PMID>
  </results_reference>
  <results_reference>
    <citation>Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer. 2011 Jul 1;117(13):3053-9. doi: 10.1002/cncr.25809. Epub 2011 Jan 24.</citation>
    <PMID>21264826</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <results_first_submitted>June 29, 2011</results_first_submitted>
  <results_first_submitted_qc>July 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2012</results_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>David Bush</investigator_full_name>
    <investigator_title>Principal Inverstigator</investigator_title>
  </responsible_party>
  <keyword>Proton</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Liver Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with a diagnosis of hepatocellular carcinoma were recruited from the hepatology clinic at Loma Linda University Medical Center to participate in this trial.</recruitment_details>
      <pre_assignment_details>Patients with documented metastatic disease were excluded from this trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Proton Beam Therapy</title>
          <description>Patients received 63Gy in three weeks with proton beam.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Proton Beam Therapy</title>
          <description>Patients received 63Gy in three weeks with proton beam.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>3-year Survival Without Tumor Progression for Patients Within the Milan Criteria</title>
        <description>Percent of participants alive and without tumor progression 3 years following treatment.</description>
        <time_frame>3 months</time_frame>
        <population>Participants that were within the Milan criteria</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Beam Therapy</title>
            <description>Patients received 63Gy in three weeks with proton beam.</description>
          </group>
        </group_list>
        <measure>
          <title>3-year Survival Without Tumor Progression for Patients Within the Milan Criteria</title>
          <description>Percent of participants alive and without tumor progression 3 years following treatment.</description>
          <population>Participants that were within the Milan criteria</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Survival Without Tumor Progression</title>
        <description>Median time until disease progression or death</description>
        <time_frame>3 months</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Proton Beam Therapy</title>
            <description>Patients received 63Gy in three weeks with proton beam.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Survival Without Tumor Progression</title>
          <description>Median time until disease progression or death</description>
          <population>All participants</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="16" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Proton Beam Therapy</title>
          <description>Patients received 63Gy in three weeks with proton beam.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Bush MD</name_or_title>
      <organization>Radiation Medicine - Loma Linda University Medical Center</organization>
      <phone>909-558-4280</phone>
      <email>dbush@dominion.llumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

